News Quantified

ATXI – avenue therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights [Yahoo! Finance]

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit

Form S-3 AVENUE THERAPEUTICS,

Form 4 AVENUE THERAPEUTICS, For: Dec 02 Filed by: Herskowitz Neil

Form 8-K AVENUE THERAPEUTICS, For: Nov 26

Form SC 13D/A AVENUE THERAPEUTICS, Filed by: Fortress Biotech, Inc.

Form 10-Q AVENUE THERAPEUTICS, For: Sep 30

Top News Gainers

6/3 Avenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Management of Postoperative Pain 15.0%

3/30 Avenue Therapeutics Reports Full Year 2019 Financial Results and Recent Corporate Highlights 8.9%

3/30 Form 10-K AVENUE THERAPEUTICS, For: Dec 31 6.3%

12/11 Avenue Therapeutics Announces Submission of New Drug Application for IV Tramadol 4.8%

5/14 Avenue Therapeutics Inc (NASDAQ: ATXI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock. 3.3%

6/3 Avenue Therapeutics, Inc. (ATXI) CEO Dr. Lucy Lu Hosts Investor Update Call (Transcript) [Seeking Alpha] 3.3%

4/29 Form DEF 14A AVENUE THERAPEUTICS, For: Jun 16 3.2%

11/15 Avenue Therapeutics Inc (NASDAQ: ATXI) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 2.4%

12/31 Form 3 AVENUE THERAPEUTICS, For: Feb 08 Filed by: InvaGen Pharmaceuticals, Inc. 2.3%

8/12 Form 4 AVENUE THERAPEUTICS, For: Aug 08 Filed by: Vazzano Joseph Walter 2.3%

Top News Decliners

3/10 Form 4 AVENUE THERAPEUTICS, For: Mar 09 Filed by: Vazzano Joseph Walter -6.1%

8/14 Q2/2019 6/30/2019 EPS -0.430 ZacksConsensus -0.560 ActVsEst 0.130 - Beat -3.6%

4/23 Avenue Therapeutics Announces Presentation of IV Tramadol E-Posters -3.5%

10/28 Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development -3.0%

6/5 Form 4 AVENUE THERAPEUTICS, For: Jun 03 Filed by: Lu Lucy -2.9%

10/18 Avenue Therapeutics to Present Phase 3 Bunionectomy Study of IV Tramadol at the American Society of Anesthesiologists Annual Meeting -2.6%

2/13 Form 8-K AVENUE THERAPEUTICS, For: Feb 13 -2.5%

2/13 Form 4 AVENUE THERAPEUTICS, For: Feb 12 Filed by: Vazzano Joseph Walter -2.1%

3/2 Form 4 AVENUE THERAPEUTICS, For: Feb 26 Filed by: Herskowitz Neil -1.9%

5/13 Q1/2019 3/31/2019 EPS -0.820 ZacksConsensus -0.440 ActVsEst (0.380) - Miss -1.7%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day